PetMed Express: Squeezing Out Losses While Betting on White Label and a Sale-Leaseback

Q1 FY27 shows the smallest net loss in a year, but the top line keeps shrinking — and the board is weighing a $3/share takeover offer.

PETS · Earnings Call · 2026-08-13

A Narrower Loss, but a Still-Shrinking Top Line

PetMed Express (PETS) reported its fiscal first-quarter 2027 results on August 13, and the headline is a dramatic narrowing of net losses: $6.1 million versus $34.2 million in the year-ago quarter. The improvement is almost entirely attributable to the absence of a noncash goodwill impairment charge taken last year, as CEO Leslie Campbell noted: “Our net loss for the first quarter narrowed significantly to $6.1 million compared to a net loss of $34.2 million in the same period last year.” — Leslie C. G. Campbell, Chairman and Interim CEO and President · 2026-08-13 Adjusted EBITDA loss, however, actually widened slightly, from $2.7 million to $3.4 million — a sign that the fundamental operating drag persists. The top line remains under pressure. Net sales fell 19.9% year over year to $41 million. Management stresses that this marks the third consecutive quarter of revenue stabilization above $40 million, and CFO Doug Krulik pointed to “a third consecutive quarter of revenue stabilization above $40 million although a 19.9% year-over-year decline primarily driven by decline in prescription medication sales.” — Doug Krulik, Interim Principal Financial Officer and Chief Accounting Officer · 2026-08-13 The revenue trend from the fundamentals axis confirms the long-term erosion: Total Revenue peaked at $78 million in Q4 2020 and has declined to the low-$40M range, with a 38% drop over ten years and a 43% peak drawdown. Gross margin, however, ticked up slightly to 32.6% (as per the fundamentals period), and the company is aggressively cutting costs: advertising expenses fell 30.2%, and G&A declined 13.5%, driven by lower professional fees and severance.

New Levers: White Label, Real Estate, and a Takeover Bid

The more interesting story is the strategic pivot beyond the core retail pharmacy. Three developments stand out. First, the company officially launched its first large-scale white label pharmacy program with Rural King in July. This makes PetMed's pharmacy infrastructure, licensed pharmacists, and ecommerce capabilities available to Rural King's 150+ stores across 17 states. Campbell framed it as a key proof point for customer acquisition and sustainable profitability:

This partnership, which we announced in April, represents our first large scale white label pharmacy program. And we believe it is an important proof point for our strategy to efficiently grow our customer acquisition reach including by converting in store shoppers into online customers, and developing new revenue streams.
Leslie C. G. Campbell, Chairman and Interim CEO and President · 2026-08-13

The white label model is a genuine departure from the company's historical direct-to-consumer focus and directly addresses the challenge of rising customer acquisition costs. In the quarter, PetMed acquired ~70,000 new customers, with the cost of acquiring a new customer down 15% to $60 — an encouraging sign that marketing efficiency is improving, but it also underscores how expensive growth has become in this competitive market. Second, the company announced a sale-leaseback of its headquarters and distribution center in Delray Beach, Florida, for $37 million. This is a classic capital-allocation move to unlock real estate value and strengthen the balance sheet, which already had $13.1 million in cash and no debt. The 10-year lease with renewal options keeps operations in place while providing financial flexibility. As Campbell put it, “We see this transaction as a strategic next step in our ongoing commitment to sharpen our focus on our core pharmacy business, strengthen our balance sheet and optimize our asset base by unlocking the value of our real estate.” — Leslie C. G. Campbell, Chairman and Interim CEO and President · 2026-08-13 Third, and most materially for shareholders, the board disclosed receipt of an unsolicited, conditional takeover proposal from Silver Cape Investments at $3.00 per share in cash. The company's stock trades around $2.03 (as of the period), so the offer implies a ~48% premium — yet the board has not reached a determination. The mere existence of a public bid adds a fresh layer of strategic uncertainty to a story already in transition. It also aligns with global moves in the sector, where consolidation and strategic reviews are recurring themes.

Priorities Shift: From Stabilization to Expansion

Comparisons to prior calls show a clear evolution. A year ago, management was still describing a customer under pressure and a pullback in marketing. In the November 2024 call, then-CEO Sandra Campos said, “we are pushing now going after full customer acquisition” — Sandra Campos, Chief Executive Officer · 2024-11-06 and spoke of stabilizing the business. Today, the tone is more optimistic about the infrastructure: the ERP upgrade to SAP is complete, a new call center platform launched in June, and a freight agreement now speeds West Coast deliveries by up to two days. These operational improvements are meant to boost retention and lifetime value, but the financial results remain anchored in negative territory. The company continues to generate a direct clear path narrative, yet the underlying EBITDA loss signals real work ahead. The company's own advertising expenses are down 30% year over year — a deliberate cost cut — but this also explains part of the revenue decline. The challenge is to turn the white label partnerships and cost discipline into sustainable profitability without sacrificing growth. The market seems to be taking a wait-and-see approach: the stock has been flat over the past ten weeks, with a drawdown of 14% from its July peak. In sum, PetMed is executing a multi-pronged turnaround — cutting costs, modernizing technology, and now leveraging its pharmacy infrastructure as a B2B service provider. The sale-leaseback and the unsolicited bid add immediate financial flexibility and a potential liquidity event. But whether these moves can reverse a decade-long revenue slide remains the open question.